10.73MMarket Cap-0.11P/E (TTM)
4.870High4.450Low42.87KVolume4.870Open4.650Pre Close198.85KTurnover2.01%Turnover RatioLossP/E (Static)2.22MShares48.80052wk High-2.59P/B10.31MFloat Cap3.65052wk Low--Dividend TTM2.13MShs Float1200.000Historical High--Div YieldTTM9.03%Amplitude3.650Historical Low4.638Avg Price1Lot Size
Mainz Biomed Stock Forum
$Mainz Biomed (MYNZ.US)$
📊⚡️📊
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Thursday, 19th December at 8:01 am
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE: DGX), a leading ...
Mainz Biomed Forms Agreement With Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Apple’s stoc...
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
13 MINUTES AGO, 8:00 PM EST
VIA GLOBENEWSWIRE
BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the ...
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
1 minute ago, 5:00 PM PST
Via GlobeNewswire
MYNZ
Share
BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 1,367,521 units, with each unit...
No comment yet